Loading... Please wait...

Vamorolone (VBP 15) Gets Fast Track Designation for Duchenne Muscular Dystrophy

Posted by

25 March 2107

The FDA has granted Fast Track Designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy to ReveraGen BioPharma Inc.

The VISION-DMD clinical trial program for vamorolone is currently enrolling boys with DMD into clinical trials in US, Canada, Australia, Sweden, UK, and Israel (open label Phase 2a, Phase 2a extension, and Long-term extension studies). Phase 2b trials are expected to initiate enrolment later this year.

To read more : http://www.raredr.com/news/vamorolone-fast-track